Please use this identifier to cite or link to this item: http://repositorio.ufla.br/jspui/handle/1/42512
metadata.artigo.dc.title: Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays
metadata.artigo.dc.creator: Kohmer, Niko
Westhaus, Sandra
Rühl, Cornelia
Ciesek, Sandra
Rabenau, Holger F.
metadata.artigo.dc.subject: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Immunoglobulin G (IgG)
Assay
Evaluation
Plaque reduction neutralization test (PRNT)
metadata.artigo.dc.publisher: Elsevier
metadata.artigo.dc.date.issued: Aug-2020
metadata.artigo.dc.identifier.citation: KOHMER, N. et al. Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. Journal of Clinical Virology, [S.l.], v. 129, Aug. 2020.
metadata.artigo.dc.description.abstract: Serological SARS-CoV-2 assays are urgently needed for diagnosis, contact tracing and for epidemiological studies. So far, there is limited data on how recently commercially available, high-throughput immunoassays, using different recombinant SARS-CoV-2 antigens, perform with clinical samples. Focusing on IgG and total antibodies, we demonstrate the performance of four automated immunoassays (Abbott Architect™ i2000 (N protein-based)), Roche cobas™ e 411 analyzer (N protein-based, not differentiating between IgA, IgM or IgG antibodies), LIAISON®XL platform (S1 and S2 protein-based), VIRCLIA® automation system (S1 and N protein-based) in comparison to two ELISA assays (Euroimmun SARS-CoV-2 IgG (S1 protein-based) and Virotech SARS-CoV-2 IgG ELISA (N protein-based)) and an in-house developed plaque reduction neutralization test (PRNT). We tested follow up serum/plasma samples of individuals PCR-diagnosed with COVID-19. When calculating the overall sensitivity, in a time frame of 49 days after first PCR-positivity, the PRNT as gold standard, showed the highest sensitivity with 93.3% followed by the dual-target assay for the VIRCLIA® automation system with 89%. The overall sensitivity in the group of N protein-based assays ranged from 66.7 to 77.8% and in the S protein-based-assays from 71.1 to 75.6%. Five follow-up samples of three individuals were only detected in either an S and/or N protein-based assay, indicating an individual different immune response to SARS-CoV-2 and the influence of the used assay in the detection of IgG antibodies. This should be further analysed. The specificity of the examined assays was ≥ 97%. However, because of the low or unknown prevalence of SARS-CoV-2, the examined assays in this study are currently primarily eligible for epidemiological investigations, as they have limited information in individual testing.
metadata.artigo.dc.identifier.uri: https://www.sciencedirect.com/science/article/pii/S1386653220302225
http://repositorio.ufla.br/jspui/handle/1/42512
metadata.artigo.dc.language: en_US
Appears in Collections:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.